Dublin, May 08, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Osteopenia & Osteoporosis Forecast in 13 Major Markets 2017-2027" report to their offering.

This report provides the current prevalent population for Osteopenia and Osteoporosis across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Russia and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Osteopenia and osteoporosis (porous bone) are both terms which help to define the continuum of loss of bone density which leads to bone fragility and an increased risk of fractures of the hip, spine and wrist.

Loss of bone density is characterised by too little bone formation, excessive bone loss or a combination of both, typically as a result of hormonal changes, or deficiency of calcium or vitamin D.

Both osteopenia and osteoporosis remain largely under diagnosed because of their asymptomatic nature, especially in the less severe stages of bone loss.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Osteopenia and Osteoporosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

The following conditions and comorbidities are associated with loss of bone mineral density:

- Back pain
- Hypertension
- Diabetes
- Osteoarthritis
- RA
- Asthma
- Hyperlipidaemia
- Hyperthyroidism
- Cushing's syndrome
- Pituitary disease
- Multiple myeloma
- Thalassaemia major
- Bone fractures (particularly in the spine or hip)

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Frax

8. Key comorbid conditions/Features associated with the disease

9. Methodology for quantification of patient numbers

10. Top-line prevalence for Osteoporosis

11. Features of Osteoporosis patients
11.1 Cardiovascular and metabolic comorbidities
11.2 Arthritis in patients with osteoporosis
11.3 Respiratory comorbidities
11.4 Severe Osteoporosis patients

12. Top-line prevalence for Osteopenia

13. Abbreviations used in the report

14. Patient-Based Offering

15. Online Pricing Data and Platforms

16. References

17. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/tkv3dp/osteopenia_and

CONTACT: Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs